Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,232 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,064
- Phase 1822
- Phase 1/Phase 2446
- Phase 3425
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis344
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia98
- Autoimmune Diseases81
- Follicular Lymphoma73
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)75
- Assistance Publique - Hôpitaux de Paris69
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center62
- AstraZeneca57
- Mayo Clinic47
- City of Hope Medical Center46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama180
- Florida142
- Arizona140
- New York122
- Massachusetts120
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,232 total
- NCT05352919Enrolling by invitationPhase 3
Long-term study of litifilimab for lupus symptom control
This study follows people with systemic lupus erythematosus (SLE) who already took part in an earlier, 1-year placebo-controlled trial. It looks at the long-term safety of litifilimab and whether it helps improve lupus symptoms over time.
Phoenix, ArizonaAges 18 years+ - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Tucson, ArizonaAges 18 years+ - NCT07438496RecruitingPhase 3
Study of nipocalimab for moderate to severe lupus
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
Beverly Hills, CaliforniaAges 18–75 - NCT07027826Recruiting
String test for eosinophilic esophagitis in African patients
This study tests a new, less invasive way (the Esophageal String Test) to look for signs of eosinophilic esophagitis—an allergic condition that can make swallowing painful or difficult. It is for people of African descent who have trouble swallowing and are already having an endoscopy.
Bethesda, MarylandAges 18–65 - NCT05621291Recruiting
Sequencing test to guide care after CD19 CAR T in kids
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Los Angeles, CaliforniaAges 1–25 - NCT07768371RecruitingPhase 3
Remibrutinib for peanut, milk, or egg allergies
This study tests an investigational drug called remibrutinib to see if it can reduce allergic reactions to peanuts, milk, or eggs. It is for people aged 12 to 65 who have been diagnosed with a food allergy and are willing to participate in food challenges.
Los Angeles, CaliforniaAges 12–65 - NCT06717347RecruitingPhase 3
Study of a new drug combo for untreated DLBCL
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Mobile, AlabamaAges 18 years+ - NCT07123454RecruitingPhase 1/Phase 2
Study of AZD4512 for relapsed or refractory B-cell lymphoma
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
Irvine, CaliforniaAges 18 years+ - NCT07634471RecruitingPhase 2/Phase 3
Testing MK-1045 and Rituximab for Untreated Follicular Lymphoma
This trial tests a new drug called MK-1045 combined with rituximab (a standard lymphoma treatment) in people who have never been treated for follicular lymphoma. The goal is to see if this combination works better than current treatments.
Durham, North CarolinaAges 18 years+ - NCT07215949RecruitingPhase 3
Zilucoplan for severe myasthenia gravis flare-ups
This trial tests zilucoplan, a daily injection, to treat severe muscle weakness from myasthenia gravis that requires hospital care. It may help you recover faster and avoid needing a breathing tube.
Tampa, FloridaAges 18 years+ - NCT06948110Recruiting
Searching for genes linked to autoimmune diseases
This study looks for genes that may be linked to autoimmune diseases by comparing the DNA of people with these conditions to healthy family members or volunteers. If you have an autoimmune disease or are a healthy person interested in helping research, this study may help scientists understand why these diseases run in families.
Bethesda, MarylandAges 18–115 - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT07647510RecruitingPhase 3
Testing Claseprubart for Generalized Myasthenia Gravis
This study tests whether a new drug called claseprubart can help adults with generalized myasthenia gravis (a condition where muscles get weak and tired easily). The drug works by targeting part of the immune system that damages muscles.
Boca Raton, FloridaAges 18–80 - NCT06904066RecruitingPhase 1
Custom T cells for blood cancers with specific mutations
This trial tests a personalized treatment where your immune cells are collected, modified to recognize unique cancer markers (neoantigens) from TP53 or RAS mutations, and returned to fight blood cancers like AML, MDS, or multiple myeloma.
Bethesda, MarylandAges 18–120 - NCT07599982Recruiting
Safety test of MODI insulin adjustment system for adults
This trial tests MODI, a smartphone app that helps automatically adjust your insulin doses based on blood sugar readings from a continuous glucose monitor. The study checks if this system is safe and helps people with type 1 or type 2 diabetes manage their blood sugar better.
Baltimore, MarylandAges 18–80 - NCT07363590RecruitingPhase 1
Study of MK-1045 for lupus or rheumatoid arthritis
This study tests a new drug, MK-1045, for people with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how it affects your condition.
Southport, QueenslandAges 18–75 - NCT05327114RecruitingPhase 2/Phase 3
Nipocalimab for adults with chronic inflammatory CIDP nerve disease
This trial tests nipocalimab (an antibody medicine) to improve symptoms and control activity in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. It may help reduce disease activity and disability, while checking safety.
Centennial, ColoradoAges 18 years+ - NCT06687772RecruitingPhase 2
Preventing brain relapse in high-risk lymphoma with stem cell transplant
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
St Louis, MissouriAges 18–75 - NCT07258511RecruitingPhase 3
Comparing a new drug to Teclistamab for advanced multiple myeloma
This study tests a new experimental drug (JNJ-79635322) compared to another targeted immunotherapy (Teclistamab) for people with multiple myeloma that has returned or not responded after several prior treatments.
Phoenix, ArizonaAges 18 years+ - NCT06631638Recruiting
New hip replacement study using smart navigation
This study tests a hip replacement system that uses a special navigation tool to help the surgeon place the new hip cup more precisely. It may lead to better long-term results and fewer complications.
Gainesville, FloridaAges 21 years+ - NCT07519772RecruitingPhase 1/Phase 2
Testing MK-1045 for Hard-to-Treat Lymphoma
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
Denver, ColoradoAges 18 years+ - NCT06948097RecruitingPhase 1
Testing fostamatinib for lung transplant patients with new donor-specific antibodies
This trial tests a drug called fostamatinib to see if it is safe and tolerable for lung transplant patients who develop new antibodies against their donor lung. It aims to prevent rejection without harming the new lung.
Stanford, CaliforniaAges 18–99 - NCT07570173RecruitingPhase 2/Phase 3
MK-1045 for Hard-to-Treat B-Cell Leukemia
This trial tests a new drug called MK-1045 in patients whose acute lymphoblastic leukemia (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can help control the cancer when other options haven't worked.
Copenhagen, Capital RegionAges 12 years+ - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,232 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,656 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.